This study aims to determine the relationship between flortaucipir PET uptake and tau burden assessed quantitatively by postmortem neuropathological studies in patients with varying degrees of AD neuropathological changes (ADNC), and non-AD 3R and 4R tauopathies. Here, MAPT is linked to Alzheimer disease.